Gladman DD, Urowitz MB, Rahman P et al (2003) Accrual of organ damage over time in patients with systemic lupus erythematosus. J Rheumatol 30:1955–1959

PubMed  Google Scholar 

Mathian A, Pha M, Haroche J et al (2020) Withdrawal of low-dose prednisone in SLE patients with a clinically quiescent disease for more than 1 year: a randomized clinical trial. Ann Rheum Dis 79:339–346. https://doi.org/10.1136/annrheumdis-2019-216303

Article  CAS  PubMed  Google Scholar 

Ji L, Xie W, Zhang Z (2021) Low-dose glucocorticoids should be withdrawn or continued in systemic lupus erythematosus? A systematic review and meta-analysis on risk of flare and damage accrual. Rheumatology 60:5517–5526. https://doi.org/10.1093/rheumatology/keab149

Article  PubMed  Google Scholar 

Wiebe E, Huscher D, Schaumburg D et al (2022) Optimising both disease control and glucocorticoid dosing is essential for bone protection in patients with rheumatic disease. Ann Rheum Dis 81:1313–22. https://doi.org/10.1136/annrheumdis-2022-222339

Article  CAS  PubMed  Google Scholar 

Doria A, Gatto M, Zen M et al (2014) Optimizing outcome in SLE: treating-to-target and definition of treatment goals. Autoimmun Rev 13:770–7. https://doi.org/10.1016/j.autrev.2014.01.055

Article  CAS  PubMed  Google Scholar 

Franklyn K, Lau CS, Navarra SV et al (2016) Definition and initial validation of a Lupus Low Disease Activity State (LLDAS). Ann Rheum Dis 75:1615–21. https://doi.org/10.1136/annrheumdis-2015-207726

Article  CAS  PubMed  Google Scholar 

van Vollenhoven RF, Bertsias G, Doria A et al (2021) 2021 DORIS definition of remission in SLE: final recommendations from an international task force. Lupus Sci Med 8:e000538. https://doi.org/10.1136/lupus-2021-000538

Article  PubMed  PubMed Central  Google Scholar 

Navarra SV, Guzmán RM, Gallacher AE et al (2011) Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet 377:721–31. https://doi.org/10.1016/S0140-6736(10)61354-2

Article  CAS  PubMed  Google Scholar 

Furie RA, Wallace DJ, Aranow C et al (2018) Long-term safety and efficacy of belimumab in patients with systemic lupus erythematosus: a continuation of a seventy-six-week phase III parent study in the United States. Arthr Rheumatol 70:868–77. https://doi.org/10.1002/art.40439

Article  CAS  Google Scholar 

Sthoeger Z, Lorber M, Tal Y et al (2017) Anti-BLyS treatment of 36 israeli systemic lupus erythematosus patients. Isr Med Assoc J 19:44–48

PubMed  Google Scholar 

Zhang F, Bae SC, Bass D et al (2018) A pivotal phase III, randomised, placebo-controlled study of belimumab in patients with systemic lupus erythematosus located in China, Japan and South Korea. Ann Rheum Dis 77:355–63. https://doi.org/10.1136/annrheumdis-2017-211631

Article  CAS  PubMed  Google Scholar 

Ginzler EM, Wallace DJ, Merrill JT et al (2014) Disease control and safety of belimumab plus standard therapy over 7 years in patients with systemic lupus erythematosus. J Rheumatol 41:300–9. https://doi.org/10.3899/jrheum.121368

Article  CAS  PubMed  Google Scholar 

Garval E, Pennaforte JL, Jaussaud R et al (2018) Lupus erythematosus treatment with belimumab in daily practice: retrospective study of 15 patients. Ann Dermatol Venereol 145:5–12. https://doi.org/10.1016/j.annder.2017.07.008

Article  CAS  PubMed  Google Scholar 

Scheinberg MA, Golmia AP, Golmia RP et al (2021) Lupus low disease activity (SLE) in patients treated with belimumab: a single-center real-life experience (2016–2019). Clin Rheumatol 40:923–7. https://doi.org/10.1007/s10067-020-05315-w

Article  PubMed  Google Scholar 

Fanouriakis A, Adamichou C, Koutsoviti S et al (2018) Low disease activity—irrespective of serologic status at baseline—associated with reduction of corticosteroid dose and number of flares in patients with systemic lupus erythematosus treated with belimumab: A real-life observational study. Semin Arthritis Rheum 48:467–74. https://doi.org/10.1016/j.semarthrit.2018.02.014

Article  CAS  PubMed  Google Scholar 

Fernandes BM, Barreira S, Fonseca JE et al (2020) Belimumab in the treatment of Portuguese Systemic Lupus Erythematosus patients: a real-life multicenter study. Acta Reumatol Port 45:170–176

PubMed  Google Scholar 

Andreoli L, Reggia R, Pea L et al (2014) Belimumab for the treatment of refractory systemic lupus erythematosus: real-life experience in the first year of use in 18 Italian patients. Isr Med Assoc J 16:651–653

PubMed  Google Scholar 

Anjo C, Mascaró JM Jr, Espinosa G et al (2019) Effectiveness and safety of belimumab in patients with systemic lupus erythematosus in a real-world setting. Scand J Rheumatol 48:469–73. https://doi.org/10.1080/03009742.2019.1603324

Article  CAS  PubMed  Google Scholar 

Aringer M, Costenbader K, Daikh D et al (2019) 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. Ann Rheum Dis 78:1151–9. https://doi.org/10.1136/annrheumdis-2018-214819

Article  PubMed  Google Scholar 

European medicines agency - Benlysta [online]. (2023) https://www.ema.europa.eu/en/medicines/human/EPAR/benlysta . Accessed 21 October 2023.

Buttgereit F (2002) Standardised nomenclature for glucocorticoid dosages and glucocorticoid treatment regimens: current questions and tentative answers in rheumatology. Ann Rheum Dis 61:718–22. https://doi.org/10.1136/ard.61.8.718

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gatto M, Saccon F, Zen M et al (2020) Early disease and low baseline damage as predictors of response to belimumab in patients with Systemic Lupus Erythematosus in a real-life setting. Arthr Rheumatol 72:1314–24. https://doi.org/10.1002/art.41253

Article  CAS  Google Scholar 

Furie R, Petri M, Zamani O et al (2011) A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthr Rheum 63:3918–30. https://doi.org/10.1002/art.30613

Article  CAS  Google Scholar 

Collins CE, Cortes-Hernández J, Garcia MA et al (2020) Real-World effectiveness of belimumab in the treatment of Systemic Lupus Erythematosus: pooled analysis of multi-country data from the OBSErve studies. Rheumatol Ther 7:949–65. https://doi.org/10.1007/s40744-020-00243-2

Article  PubMed  PubMed Central  Google Scholar 

Sbeih N, Mathian A, Chambrun MP et al (2020) Achieving lupus low-disease activity and remission states under belimumab in refractory systemic lupus erythematosus: time and organ involvement matter. Ann Rheum Dis 79:e148–e148. https://doi.org/10.1136/annrheumdis-2019-215732

Article  PubMed  Google Scholar 

Parodis I, Johansson P, Gomez A et al (2019) Predictors of low disease activity and clinical remission following belimumab treatment in systemic lupus erythematosus. Rheumatology (Oxford) 58:2170–6. https://doi.org/10.1093/rheumatology/kez191

Article  CAS  PubMed  Google Scholar